Drug Resistance to Anti-Tuberculosis Drugs: A Cross-Sectional Study From Makkah, Saudi Arabia

Ahmad M. Al-Hayani, Shady A. Kamel, Sami S. Almudarra, Majed Alhayani, Ahmed Abu-Zaid

1. Saudi Field Epidemiology Training Program, Ministry of Health, Riyadh, SAU 2. College of Medicine, King Abdulaziz University, Jeddah, SAU 3. College of Graduate Health Sciences, The University of Tennessee Health Science Center, Memphis, USA

Corresponding author: Ahmad M. Al-Hayani, ahmadmh.amh@gmail.com

Abstract

Aim

The aim of this study was to investigate the patterns and determinants of drug resistance to tuberculosis (TB) in a large population from Makkah, Saudi Arabia.

Methods

A retrospective, cross-sectional cohort study was conducted on all patients with TB who were referred to the National Tuberculosis Prevention Program in Makkah, Saudi Arabia, between January 2016 and September 2020. For each TB case, demographic data were collected in addition to the results of drug susceptibility testing (DST) for anti-TB drugs. The Statistical Package for Social Sciences (SPSS) software for Windows, version 23 (IBM Corporation, Armonk, NY, USA), was used for the statistical analysis.

Results

A total of 472 TB-confirmed cases were included in the analysis. The mean ± standard deviation of the age was 58.5 ± 17.7 years. The vast majority of patients were male (62.7%) and had pulmonary TB (91.7%). Only a small proportion of the patients with TB had diabetes mellitus (8.5%). Overall, the prevalence of monodrug-resistant TB ranged from 2.1% to 5.4%. Specifically, the prevalence of monodrug-resistant TB to isoniazid and streptomycin was ranked first and was equal to 3.4%. Pyrazinamide had the lowest prevalence of monodrug-resistant TB (2.1%). The prevalence of polydrug-resistant TB (PDR-TB) and multidrug-resistant TB (MDR-TB) was 1.5%. In the univariate analysis, sex (male) was the only sociodemographic factor that significantly correlated with a higher prevalence of MDR-TB.

Conclusions

This is the second study from Makkah to analyze the prevalence and associated risk factors of MDR-TB among patients from Makkah. Our data demonstrated that the prevalence of monodrug-resistant TB and MDR-TB was low (2.1%-3.4% and 1.5%, respectively). Diabetes mellitus was not a substantial factor correlated with a higher occurrence of MDR-TB. Additional epidemiologic studies are required to validate our results.

Introduction

Tuberculosis (TB) continues to be a chief healthcare predicament worldwide and a prominent cause of mortality from a solitary infectious disease agent [1]. More than 10 million new cases of TB and 1.5 million mortalities were documented in 2018 [2]. By the end of 2035, the World Health Organization (WHO) aspires to accomplish a dramatic decline in the frequency of TB and its mortality by 90% and 95%, respectively [3].

Although TB can be successfully cured in the vast majority of patients, some individuals develop resistance to first-line anti-TB therapy, comprising isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin [4]. Polydrug-resistant TB (PDR-TB) occurs when a patient develops resistance to two or more first-line anti-TB agents other than isoniazid and rifampicin [5]. On the other hand, multidrug-resistant TB (MDR-TB) occurs when a patient develops resistance to both isoniazid and rifampicin with or without other first-line agents [6]. Approximately half a million TB cases are diagnosed with MDR-TB [2]. Unfortunately, MDR-TB is associated with costly treatment expenses, lower rates of treatment success, and higher burdens of morbidity and mortality [7-9].

TB remains a major public health issue in Saudi Arabia. According to the most recent statistics, the yearly TB incidence is 10 per 100,000 individuals [2]. A large national study from Saudi Arabia demonstrated that MDR-TB rates among new and previously treated cases were 1.8% and 15.9%, respectively [10]. Other national registry data from the Ministry of Health stated that the prevalence rate of MDR-TB was 4.4% [11].
The occurrence rate of MDR-TB varies according to the region/city of the report [12], and these geographic differences need to be recognized. Makkah, a city in the Western province of Saudi Arabia, serves as the principal hub for two mass religious gatherings, namely the Hajj and Umrah pilgrimages. While Hajj pilgrimage takes place annually by the end of the Hijri calendar, Umrah pilgrimage takes place throughout the year. These two pilgrimages attract millions of individuals worldwide, including Asian and African countries with a high TB burden [1]. Thus, it is critical to explore the prevalence and patterns of MDR-TB in this vulnerable city. So far, only one study has aimed to explore the prevalence and determinants of MDR-TB in Makkah [13]. This study was conducted at the Al-Noor Specialist Hospital and evaluated the records of only 158 patients with TB-confirmed cases. Hence, additional large-sized data are warranted to provide more comprehensive and high-quality evidence.

This study aimed to investigate the patterns and determinants of drug resistance to TB among a large sample from Makkah, Saudi Arabia.

Materials And Methods

The study protocol was approved by the Institutional Review Board of King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. A retrospective, cross-sectional cohort study was conducted on all TB-confirmed patients, irrespective of age, who were referred to the National Tuberculosis and Prevention Program in Makkah, Saudi Arabia, between January 2016 and September 2020.

The TB diagnosis was confirmed by various methods, including chest radiography, sputum culture, microscopy, or molecular assays. TB resistance was established using drug susceptibility testing (DST). To isolate and identify the mycobacterium agent, Ziehl-Neelsen (ZN) staining was performed to examine acid-fast bacilli. Culture and DST were performed using the mycobacteria growth indicator tube (MGIT) medium and BACTEC MGIT 960 instrument (Becton, Dickinson and Company, Maryland, United States of America), as reported previously [14]. The final drug concentrations utilized for DST included 5 μg/ml for ethambutol, 0.1 μg/mL for streptomycin, 1 μg/mL for rifampicin, 0.1 μg/mL for isoniazid, and 25 μg/mL for pyrazinamide. For selected samples, the GenXpert Mycobacterium tuberculosis complex/resistance to rifampicin (MTB/RIF) assay (Cepheid, California, United States of America) was used to screen for the Mycobacterium tuberculosis complex and resistance to rifampicin.

Demographic data were collected for each TB case (i.e., age, sex, nationality, disease site, diabetes mellitus, renal failure, acquired immunodeficiency syndrome, immunosuppression, cancer, and Bacillus Calmette-Guérin vaccination) in addition to the results of the DST for TB. DST results focused on identifying the rates of monodrug-resistant TB (resistance to one anti-TB drug), PDR-TB (resistance to two or more anti-TB drugs other than isoniazid and rifampicin), and MDR-TB (resistance to at least both isoniazid and rifampicin with or without resistance to other drugs).

The Statistical Package for Social Sciences (SPSS) software for Windows, version 23, was used for statistical analysis (IBM Corporation, Armonk, NY, USA). Descriptive data were presented as numbers and percentages or means and standard deviations, as appropriate. The Chi-squared test was used to examine correlations between select patient demographics and the occurrence of MDR-TB.

Results

A total of 472 records of TB-confirmed cases were included in the analysis. Table 1 summarizes the sociodemographic characteristics of the patients. The mean ± standard deviation of age was 38.5 ± 17.7 years (range: 2-101 years). The prevalence of TB was equally divided between Saudi and non-Saudi nationals (50.4% and 49.6%, respectively). Most patients were male (62.7%) and had pulmonary TB (91.7%). Only a small proportion of TB patients had diabetes mellitus (8.5%), renal failure (23%), acquired immunodeficiency syndrome (3%), immunosuppression (1.9%), and cancer (1.3%). Equally, 5.7% of patients had a previous history of TB and received the Bacillus Calmette-Guérin vaccine.
| Sociodemographic                  | n (%)      |
|----------------------------------|------------|
| **Nationality**                  |            |
| Saudi                            | 238 (50.4) |
| Non-Saudi                        | 234 (49.6) |
| **Sex**                          |            |
| Male                             | 296 (62.7) |
| Female                           | 176 (37.7) |
| **Type**                         |            |
| Pulmonary                        | 433 (91.7) |
| Extra-pulmonary                  | 36 (7.6)   |
| Both                             | 3 (0.6)    |
| **Diabetes mellitus**            |            |
| Yes                              | 40 (8.5)   |
| No                               | 432 (91.5) |
| **Renal failure**                |            |
| Yes                              | 11 (2.3)   |
| No                               | 461 (97.7) |
| **Acquired immunodeficiency syndrome** |      |
| Yes                              | 14 (3)     |
| No                               | 458 (97)   |
| **Immunosuppression**            |            |
| Yes                              | 9 (1.9)    |
| No                               | 463 (98.1) |
| **Cancer**                       |            |
| Yes                              | 7 (1.5)    |
| No                               | 465 (98.5) |
| **Bacillus Calmette-Guérin vaccine** |          |
| Yes                              | 27 (5.7)   |
| No                               | 445 (94.3) |
| **Previous history of tuberculosis** |       |
| Yes                              | 27 (5.7)   |
| No                               | 445 (94.3) |

**TABLE 1: The sociodemographics of patients.**

Table 2 outlines the patterns of drug resistance to anti-TB drugs. Overall, the prevalence of monodrug-resistant TB ranged from 2.1% to 5.4%. Specifically, the prevalence of monodrug-resistant TB to isoniazid and streptomycin was ranked first and was equal to 3.4%. Pyrazinamide had the lowest prevalence of monodrug-resistant TB (2.1%). The prevalence of PDR-TB and MDR-TB was 1.5%.
### TABLE 2: Patterns of resistance to anti-tuberculosis drugs.

| Type of tuberculosis resistance                  | n (%) |
|--------------------------------------------------|-------|
| **Monodrug-resistant tuberculosis**               |       |
| Isoniazid                                         | 16 (3.4) |
| Pyrazinamide                                      | 10 (2.1) |
| Ethambutol                                        | 12 (2.5) |
| Rifampicin                                        | 13 (2.8) |
| Streptomycin                                      | 16 (3.4) |
| **Polydrug-resistant tuberculosis**               |       |
| Pyrazinamide plus ethambutol                      | 5 (1.1) |
| Pyrazinamide plus streptomycin                    | 7 (1.5) |
| Ethambutol plus streptomycin                      | 7 (1.5) |
| **Multidrug-resistant tuberculosis**              |       |
|                                                 | 7 (1.5) |

Table 3 depicts the univariate analysis between the patient sociodemographics and the prevalence of MDR-TB. Sex (male) was the only sociodemographic factor that significantly correlated with a higher prevalence of MDR-TB (all the seven cases of MDR-TB occurred in male individuals).

### TABLE 3: Univariate analysis (two-tailed chi-squared test) between patient sociodemographics and prevalence of multidrug-resistant tuberculosis.

| Sociodemographic variable             | p-value |
|---------------------------------------|---------|
| Nationality                           | 0.244   |
| Sex                                   | 0.04    |
| Tuberculosis type                     | 0.726   |
| Diabetes mellitus                     | 0.541   |
| Renal failure                         | 0.681   |
| Acquired immunodeficiency syndrome    | 0.641   |
| Immunosuppression                     | 0.710   |
| Cancer                                | 0.744   |
| Bacillus Calmette-Guérin vaccine      | 0.511   |
| Previous history of tuberculosis      | 0.511   |

Statistical significance was determined as p-value <0.05.

### Discussion

This is one of the limited studies from the Western province of Saudi Arabia to scrutinize the prevalence and associated risk factors of MDR-TB among patients from Makkah. Our study revealed that the prevalence of monodrug-resistant TB ranged from 2.1% to 3.4%. Conversely, the prevalence rates for PDR-TB and MDR-TB were 1.5%. Additionally, diabetes and a previous history of TB were not substantial factors correlated with a higher occurrence of MDR-TB.

In our study, the distribution of TB cases was roughly divided between Saudi and non-Saudi nationals. This finding suggests that expatriates contribute substantially to the overall TB prevalence in Makkah, which harbors two large-sized religious gatherings and welcomes millions of people from all over the world.

Our data revealed that the prevalence rate of MDR-TB among TB-confirmed patients from Makkah was low (1.5%). Our reported figure differed from two national registry data reporting MDR-TB prevalence rates of
15.9\% \[10\] and 4.4\% \[11\]. Indeed, MDR-TB remains an ongoing encumbrance and several national reports from Saudi Arabia have revealed that MDR-TB rates vary substantially in accordance with the reporting region/city \[12\]. For example, it has been documented that the rate of MDR-TB was 1.4\% in the Eastern provinces \[12\], 20.6\% in Najran \[15\], 2.5-6.7\% in Riyadh \[16,17\], 4\% in Al-Madinah Al-Munawarah \[18\], and 20\% in Jeddah \[19\].

With regard to Makkah, only one study thus far has endeavored to examine the prevalence and determinants of MDR-TB \[13\]. This study was a single-center experience from the Al-Noor Specialist Hospital, reporting only a total of 158 patients. This study revealed that the prevalence rate of MDR-TB was 5\% \[13\]. Moreover, this study demonstrated that age, lung disease, and a previous history of TB were substantial factors correlated with MDR-TB \[13\]. Our present study is characterized by a larger sample size and a more holistic representation of Makkah population, as data were derived from the registry of the Central TB Laboratory in Makkah.

Isoniazid and streptomycin were the two most frequent monodrug-resistant anti-TB agents (3.4\%). Our data mirrored the findings of another study conducted in Makkah by Sambas et al. \[13\] and other studies conducted in Jeddah \[19\], Riyadh \[20\], and Dhahran \[21\]. Moreover, our data were consistent with a comparable pattern previously chronicled by two national registries in Saudi Arabia \[10,11\]. Indeed, isoniazid is the most commonly effective yet most frequently resistant anti-TB agent worldwide \[22\].

Sambas et al. \[13\] revealed that age, lung disease, and a previous history of TB were substantial factors correlated with MDR-TB among patients from Makkah. However, these observations did not occur in our study. The lack of statistically significant differences in our study between the abovementioned risk factors and hazard of MDR-TB could be ascribed to the small number of MDR-TB cases (1.5\%). The correlation between age and the hazard of MDR-TB is inconsistent across the published literature. While some studies revealed a positive relationship between advanced age and risk of MDR-TB \[15,23\], other studies from Asia \[11\] and Europe \[24\] found a negative correlation. On the other hand, several studies have identified no significant connection between age and risk of MDR-TB \[25-27\]. Earlier studies depicted a positive link between coexisting chronic diseases, such as diabetes mellitus and the risk of MDR-TB \[28\]. In addition, a prior history of TB has been extensively recognized as a substantial contributing factor to MDR-TB \[10,11\]. Our study revealed that male sex was positively correlated with a higher rate of MDR-TB, consistent with earlier systematic reviews \[24,29\].

It is critical to gauge the extent of resistance to TB, particularly the prevalence rates of monodrug-resistant TB and MDR-TB. This is because resistance to anti-TB drugs is disadvantageously linked to limited therapeutic alternatives. Also, resistance to anti-TB drugs demands the utility of several costly drugs which are associated with high toxicities. Moreover, MDR-TB is unfavorably associated with higher morbidity and mortality compared to drug-susceptible TB. Lastly, MDR-TB is inconveniently correlated with higher healthcare costs \[7,30\]. Epidemiologic studies on anti-TB drug resistance are crucial to healthcare policymakers and stakeholders. Such studies permit the development of proper surveillance initiatives to ensure effective control and prevention of MDR-TB, along with training the treating physicians about the recommended initial anti-TB regimens for a particular geographic region.

Our study has several strengths. It is the second-ever study about the prevalence of MDR-TB in Makkah; however, with a larger sample size than that reported by Sambas et al. \[15\]. Our data also included only TB-confirmed cases extracted from the Central TB Laboratory in Makkah, highlighting a broader representation of the population of Makkah. Nevertheless, our study has some limitations. Such limitations comprise the retrospective and cross-sectional study design, which does not reliably permit establishing a temporal correlation between the exposure and outcome variables. Also, due to the small number of MDR-TB cases, it was not possible to confidently identify relationships between risk of MDR-TB and some clinical and demographic parameters.

Conclusions

This is the second-ever study from the Western province of Saudi Arabia to analyze the prevalence and associated risk factors of MDR-TB among patients from Makkah. Our data demonstrated that the prevalence rates of monodrug-resistant TB and MDR-TB were low (2.1\%–3.4\% and 1.5\%, respectively). Diabetes and a previous history of TB were not substantial factors correlated with a higher occurrence of MDR-TB. Additional epidemiologic studies are required to validate our results.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Institutional Review Board at King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. issued approval H-01-R-012. The study protocol was approved by the Institutional Review Board at King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Acknowledgements

The authors would like to thank the Ministry of Health in Saudi Arabia and the National Tuberculosis & Prevention Program for providing the data requested. Additionally, the authors would like to thank Jomanh Al-Hayani for her help in data cleansing and preparation for analysis.

References

1. MacNeil A, Glaziou P, Simanadin C, Date A, Maloney S, Floyd K: Global epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020, 69:281-5. 10.15585/mmwr.mm6912a2

2. Global Tuberculosis Report 2019. (2019). Accessed: April 29, 2021: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-report-2019.

3. WHO End TB Strategy. (2015). Accessed: April 29, 2021: https://www.who.int/tb/post/2015_strategy/en/.

4. Villarino ME, Geiter LJ, Simone PM: The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep. 1992, 107:616-25.

5. Khawwam JL, Nath D, Chakraborty S: Drug resistant tuberculosis: a review. Comp Immunol Microbiol Infect Dis. 2021, 74:101574. 10.1016/j.cimid.2020.101574

6. Mukherjee JS, Rich ML, Socci AR, et al.: Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004, 363:474-81. 10.1016/S0140-6736(04)15496-2

7. Rajbhandary SS, Marks SM, Bock NN: Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004, 8:1012-6.

8. Alene KA, Yi H, Viney K, et al.: Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017, 17:573. 10.1186/s12879-017-2662-3

9. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A: Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One. 2015, 10:e0119352. 10.1371/journal.pone.0119352

10. Al-Hajid S, Varghese B, Shoukri MM, et al.: Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey. Antimicrob Agents Chemother. 2003, 57:2161-6. 10.1128/AAC.02405-12

11. Al-Awaidy ST, Al-Hamdan N: Anti-TB drugs in Saudi Arabia. Drug Targets. 2018, 18:249.

12. Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G: Drug-resistant tuberculosis in patients with pulmonary tuberculosis in Zahedan, Southeastern Iran. J Clin Tuberc Lung Dis. 2020, 5:128-32.

13. Faustini A, Hall AJ, Perucci CA: Risk factors for multidrug resistant tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. J Epidemiol Glob Health. 2012, 2:57-60. 10.1016/j.jegh.2011.10.001

14. Ali Chaudhry L, Rambhala N, Al-Shammri AS, Al-Tawfiq JA: Multidrug-resistant tuberculosis patients in Makkah, Saudi Arabia. Int J Tuberc Lung Dis. 2004, 8:1007-11. 10.1016/s1087-2135(03)00185-2

15. Al-Heajid S, Varghese B, Shoukri MM, et al.: Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey. Antimicrob Agents Chemother. 2003, 57:2161-6. 10.1128/AAC.02405-12

16. Al-Tawfiq JA, Al-Muraikhy AA, Abed MS: Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015. Antimicrob Resist Infect Control. 2018, 7:12. 10.1186/s13756-018-0306-4

17. Ali Chaudhry L, Rambhala N, Al-Shammri AS, Al-Tawfiq JA: Patterns of antitubercular drug resistance in Eastern Saudi Arabia: a 7-year surveillance study from 2003 to 6-2010. J Epidemiol Glob Health, 2012, 2:57-60. 10.1016/j.jegh.2011.10.001

18. Sambhav MR, Rbhani U, Al-Gerthany MM, et al.: Prevalence and determinants of multidrug-resistant tuberculosis in Makkah, Saudi Arabia. Infect Drug Resist. 2020, 13:4051-8. 10.2147/IDR.S227477

19. Tenover FC, Crawford JT, Huehner RE, Geiter LJ, Horshour CB Jr, Good RC: The resurgence of tuberculosis: is your laboratory ready?. J Clin Microbiol. 1995, 31:767-70. 10.1128/jcm.31.4.767-770.1995

20. Asaad AM, Alqahiti MM: Primary anti-tuberculosis drugs resistance of pulmonary tuberculosis in Southwest Saudi Arabia. Infect Public Health. 2012, 5:281-5. 10.1016/j.ijph.2012.03.003

21. Kordy FN, Al-Thawadi S, Alrahi A: Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis. 2004, 8:1007-11.

22. Alateah SM, Othman MW, Ahmed M, Al Amo MS, Al Shehini N, Aljan HH: A retrospective study of tuberculosis prevalence amongst patients attending a tertiary hospital in Riyadh, Saudi Arabia. J Clin Tuberc Other Mycobact Dis. 2020, 21:100185. 10.1016/j.ctoeb.2020.100185

23. Elhassan MM, Hemeg HA, Emelkki MA, Turkistani KA, Abdul-Aziz AA: Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia. Infect Disord Drug Targets. 2017, 17:14-23. 10.2174/1871525716661161104242

24. Khan MY, Kinsara AJ, Osoho AO, Wall S, Samman Y, Memish Z: Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia. Int J Antimicrob Agents. 2001, 17:415-8. 10.1016/S0924-8579(01)00298-9

25. Al-Awady ST, Al-Hamdan N: Drug-susceptibility pattern of mycobacterium tuberculosis among pulmonary tuberculosis patients in Saudi Arabia. J Family Community Med. 1997, 4:65-9.

26. Al-Tawfiq JA, Al-Murazkhy AA, Abed MS: Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Cystis. 2005, 128:5289-32.

27. Sults G, Pai M: Isoniazid-resistant tuberculosis: a problem we can no longer ignore. PLoS Med. 2020, 17:e1003023. 10.1371/journal.pmed.1003023

28. Meheri K, Asselah T, Huileikos H, Wubahuyu T, Godefay H, Alaya T, Saravanan M: Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia. Can J Infect Dis Med Microbiol. 2019, 2019:2923549. 10.1186/s12879-017-00199-4

29. Faustini A, Balli A: Prevalence and determinants of multidrug-resistant tuberculosis in Europe: a systematic review. Thorax. 2006, 61:158-63. 10.1136/thx.2005.045963

30. Demile B, Zemua A, Shewey H, Xia S, Guadie A: Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis. 2018, 18:249. 10.1186/s12879-018-3167-9

31. Metanat M, Sharifi-Mood B, Shahreki S, Dawoudi SH: Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in Zahedan, Southeastern Iran. Iran Red Crescent Med J. 2012, 14:53-5.

32. Mekonnen F, Tessema B, Mekonnen F, Gelaw A, Eshetie S, Kumera G: Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis. 2015, 15:461. 10.1186/s12879-015-1202-7

33. Tegegne BS, Habtezion TD, Merebwa MM, Bergerhoff IG: Association between diabetes mellitus and multidrug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. Syst Rev. 2017, 6:6. 10.1186/s13643-017-0407-9

34. Pradita IS, Forsman LD, Bruchfeld JH, Hek E, Alferness JW: Risk factors of multidrug-resistant tuberculosis:
30. Laurence YV, Griffiths UK, Vassall A: Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics. 2015, 33:939-55. 10.1007/s40273-015-0279-6